November 11, 2019
Chugai Pharmaceutical on November 8 filed a new drug application in Japan for its anti-IL-6 receptor humanized recycling antibody satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), the company said the same day. NMOSD is a rare disease...read more